Extended release tiagabine formulations with reduced side-effects
OwnerFrancisco Javier Alvarez, Kathleen M. Apfelbaum +3inventors
InventorsFrancisco Javier Alvarez, Kathleen M. Apfelbaum, David M. Brown, Linda E. Gustavson, Russell T. Slade
Life of this patent
Estimating the term…
Abstract
Extended release tiagabine formulations that demonstrate fewer side-effects when administered to a patient.
Claims24
An extended release formulation comprising tiagabine combined in a matrix with a hydrophilic polymer selected from the group consisting of high molecular weight polyethylene oxide and hydroxypropylmethyl cellulose.
An extended release formulation comprising tiagabine encapsulated in a formulation with a hydrophobic material selected from the group consisting of waxes, glyceryl behenate, triglycerides and mixtures thereof.
An extended release formulation comprising about 0.5 to 30 wt. % tiagabine combined in a matrix having:
- a. about 15 to 80 wt. % of high molecular weight polyethylene oxide;
- b. about 5 to 80 wt. % of a filler selected from the group consisting of microcrystalline cellulose, starch, and sugars;
- c. about 0.1 to 4 wt. % of silicon dioxide;
- d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT;
- e. about 0.1 to 6 wt. % of a first lubricant selected from the group consisting of a wax, stearic acid, mineral oil, stearate and a hydrogenated vegetable oil;
- and
- f. about 0.05 to 1 wt. % of a second lubricant selected from the group consisting of magnesium stearate, calcium stearate and talc.
An extended release formulation comprising about 0.5 to 30 wt. % tiagabine combined in a matrix having:
- a. about 28 to 60 wt. % of a hydrophilic polymer selected from the group consisting of HPMC and hydroxypropyl cellulose;
- b. about 5 to 80 wt. % of a filler selected from the group consisting of microcrystalline cellulose, starch, and sugars;
- c. about 0.1 to 4 wt. % of silicon dioxide;
- d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT;
- e. about 0.1 to 6 wt. % of a first lubricant selected from the group consisting of a wax, stearic acid, mineral oil, stearate and a hydrogenated vegetable oil;
- and
- f. about 0.05 to 1 wt. % of a second lubricant selected from the group consisting of magnesium stearate, calcium stearate and talc.
An extended release formulation comprising about 0.5 to 30 wt. % tiagabine encapsulated in a formulation having:
- a. about 50 to 99.5 wt. % of a hydrophobic ingredient selected from the group consisting of glyceryl behenate, bees wax carnauba wax, triglycerides and hydrogenated vegetable oil;
- b. about 0.1 to 4 wt. % of silicon dioxide;
- and
- d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT.
An extended-release tiagabine formulation, comprising from about 4 to about 80 mg tiagabine or a salt thereof, said formulation providing a mean maximum plasma concentration of tiagabine from about 10 to 1000 ng/mL from a mean of about 2 to 8 hours after administration, and a mean minimum plasma concentration of tiagabine from about 1 to 700 ng/mL from a mean of about 22 to 26 hours after repeated administration every 24 hours through steady-state conditions.
An extended-release oral tiagabine tablet, comprising from about 4 to about 80 mg tiagabine or a salt thereof, said tablet providing a mean maximum plasma concentration of tiagabine from about 10 to 1000 ng/mL from a mean of about 2 to 8 hours after administration, and a mean minimum plasma concentration of tiagabine from about 1 to 700 ng/mL from a mean of about 22 to 26 hours after repeated administration every 24 hours through steady-state conditions.
Dependencies are inferred from the claim text.